Detalles de la búsqueda
1.
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
Br J Cancer
; 124(4): 777-785, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33191407
2.
Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
Br J Cancer
; 128(9): 1790, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055522
3.
Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation.
Clin Chem Lab Med
; 55(9): 1291-1304, 2017 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28157690
4.
Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.
Br J Cancer
; 115(12): 1575-1583, 2016 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27875525
5.
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
BMC Cancer
; 16: 123, 2016 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-26892682
6.
Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.
Int J Gynecol Cancer
; 26(1): 199-207, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26569057
7.
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.
Mol Cancer
; 14: 196, 2015 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26576679
8.
Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.
BMC Cancer
; 15: 588, 2015 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26272591
9.
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Breast Cancer Res
; 16(1): R13, 2014 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24467828
10.
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
Breast Cancer Res
; 16(1): R6, 2014 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-24447434
11.
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Breast Cancer Res Treat
; 143(1): 171-9, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24265036
12.
Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Int J Gynecol Cancer
; 24(3): 468-77, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24557434
13.
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Breast Cancer Res Treat
; 139(1): 39-49, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23592373
14.
Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.
Breast Cancer Res Treat
; 133(3): 843-51, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21748294
15.
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.
Int J Gynecol Cancer
; 21(4): 763-70, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21543938
16.
Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
Clin Cancer Res
; 27(21): 5869-5877, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34210686
17.
Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
Gynecol Oncol
; 117(2): 170-6, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20132968
18.
Genetic markers and phosphoprotein forms of beta-catenin pß-Cat552 and pß-Cat675 are prognostic biomarkers of cervical cancer.
EBioMedicine
; 61: 103049, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33096476
19.
TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer.
Biomolecules
; 10(3)2020 03 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32156073
20.
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Nat Commun
; 11(1): 2641, 2020 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32457376